Which supplements have clinical evidence, and what are their indications and recommended dosages for creatine monohydrate, taurine, calcium β‑hydroxy‑β‑methylbutyrate (Ca‑HMB), omega‑3 fatty acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), and magnesium glycinate?

Evidence-Based Supplement Recommendations

Based on the strongest available evidence, only creatine monohydrate and omega-3 fatty acids (EPA/DHA) have robust clinical support for specific indications, while Ca-HMB, taurine, and magnesium glycinate lack sufficient evidence for routine supplementation in healthy individuals.

---

Creatine Monohydrate

Creatine monohydrate is the most extensively studied and effective supplement for improving high-intensity exercise performance, muscle strength, and power 1.

Clinical Evidence & Indications

• Athletic Performance: Improves high-intensity repeated sprint performance, enhances training capacity, increases muscle strength and power, and promotes lean body mass gains 1
• Mechanism: Increases muscle creatine stores, enhancing phosphocreatine resynthesis for ATP production 1

Dosing Protocols

Loading Phase: 20 g/day divided into four equal doses (5 g each) for 5-7 days 1, 2

Maintenance Phase: 3-5 g/day as a single dose for the duration of supplementation 1

Alternative: Lower-dose approach of 2-5 g/day for 28 days avoids the 1-2 kg body mass increase associated with loading 1

Important: Concurrent consumption with ~50 g protein and carbohydrate may enhance muscle creatine uptake via insulin stimulation 1

Safety Profile

Creatine is relatively safe with few adverse effects. The most common is transient water retention during early supplementation 2. When combined with other supplements or taken at higher-than-recommended doses for several months, isolated cases of liver and renal complications have occurred 2.

---

Omega-3 Fatty Acids (EPA + DHA)

The evidence for omega-3 supplementation is highly context-dependent, with cardiovascular benefits limited to specific high-risk populations at pharmacological doses.

Clinical Evidence & Indications

For Coronary Heart Disease (CHD): 1 g/day EPA+DHA combined reduces cardiovascular events, particularly sudden cardiac death 3

For Hypertriglyceridemia: 2-4 g/day EPA+DHA lowers triglycerides by 20-40% 3, 4

• Dose-response relationship: approximately 5-10% triglyceride reduction per 1 g EPA/DHA 4
• Greater efficacy in individuals with higher baseline triglyceride levels 4

Critical Limitation: Evidence does NOT support omega-3 supplements for primary or secondary prevention of cardiovascular events in people with diabetes 5. The most recent high-quality guideline (2025) from the American Association of Clinical Endocrinology found only trivial desirable effects with EPA+DHA (≥1.8 g/day) in adults with hypertriglyceridemia on statins 6.

Dosing by Indication

General Population (Primary Prevention):

• Consume fatty fish at least twice weekly to achieve ~500 mg/day EPA+DHA 3, 7
• Supplementation NOT recommended for cardiovascular prevention 5

Documented CHD:

• 1 g/day EPA+DHA from fish or supplements 3, 7

Severe Hypertriglyceridemia (>500 mg/dL):

• 2-4 g/day EPA+DHA under physician supervision 3, 7, 4

Pregnancy:

• Up to 1 g/day EPA+DHA (or at least 500 mg DHA/day) starting before 20 weeks gestation to reduce preterm birth risk 8

Safety Concerns

Atrial Fibrillation Risk: Pharmacological doses (≥1.8 g/day) consistently increase atrial fibrillation risk 6. This requires careful monitoring, especially in patients on anticoagulants or antiplatelet medications.

Bleeding Risk: Doses >3 g/day may cause excessive bleeding and should only be used under physician care 3

LDL-C Elevation: EPA+DHA may increase LDL-C levels, requiring periodic monitoring 6

---

Calcium β-Hydroxy-β-Methylbutyrate (Ca-HMB)

Ca-HMB has limited evidence supporting its use, primarily in specific clinical populations rather than healthy individuals.

Clinical Evidence

• Dosing: 3 g/day for at least 2 weeks may contribute to increased lean mass and fat-free mass 9
• COPD Patients: When combined with EPA/DHA (2 g/day), 3 g/day Ca-HMB for 10 weeks increased net protein breakdown (potentially beneficial enhanced protein turnover), reduced fat mass, and decreased inflammatory cytokines 10
• Aging: Low-dose combination with colostrum basic protein and hyaluronic acid showed musculoskeletal benefits in aged mice, but human data are lacking 11

Critical Gap: No robust evidence supports Ca-HMB supplementation in healthy individuals for performance enhancement. The evidence is primarily from disease states (COPD) or animal models.

---

Taurine

Taurine lacks sufficient clinical evidence to recommend routine supplementation in healthy adults.

Current Status

• Taurine is recognized as physiologically important for cardiovascular, neurological, muscular, retinal, and immune function 12
• It is absent from plant foods and abundant in beef (~30 g dry beef meets daily needs) 12
• FDA-approved use: Only as a component of parenteral nutrition formulations for neonates and infants 13

No established supplementation protocols exist for healthy adults based on clinical outcomes. The evidence is primarily mechanistic rather than outcome-based.

---

Magnesium Glycinate

There is insufficient evidence to support routine magnesium supplementation (including magnesium glycinate) for glycemic control or cardiovascular outcomes in individuals without documented deficiency 5.

Key Guideline Statement

The American Diabetes Association explicitly states: "There is insufficient evidence to support the routine use of micronutrients such as chromium, magnesium, and vitamin D to improve glycemic control in people with diabetes" 5.

Supplementation should only be guided by documented serum deficiency levels, not for general health optimization.

---

Common Pitfalls to Avoid

1. Omega-3 Over-Prescription: Do not recommend omega-3 supplements for general cardiovascular prevention—the evidence does not support this, particularly in diabetic populations 5, 6

2. Ignoring Atrial Fibrillation Risk: When prescribing high-dose omega-3 (≥1.8 g/day), actively monitor for atrial fibrillation, especially in patients on anticoagulation 6

3. Creatine Loading Misconceptions: Loading is not necessary to increase muscle creatine stores—lower daily doses work but take longer 1, 2

4. Supplement Quality: Over-the-counter fish oil products are highly variable and not FDA-regulated 6. Prescription formulations ensure consistent EPA/DHA content.

5. Magnesium Without Testing: Do not supplement magnesium without documented deficiency—no evidence supports empiric use 5

6. Ca-HMB in Healthy Individuals: Evidence for Ca-HMB is limited to disease states; do not extrapolate to healthy athletic populations 10, 9